Mentifar

Memantine, the active ingredient in Mentifar, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer's disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Mentifar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering consistent quality and regulatory support for global procurement.

Mentifar (memantine) is used in the management of neurodegenerative disorders, specifically targeting glutamatergic excitotoxicity in Alzheimer's disease.

- Alzheimer's disease (moderate to severe): improves cognition and functional abilities. - Alzheimer's disease (mild to moderate) as adjunct to cholinesterase inhibitors: provides additional symptomatic benefit. - Behavioral symptoms in Alzheimer's disease: may reduce agitation and improve overall patient management.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, may require dietary adjustment. - Fatigue: feeling of tiredness, usually improves over time.

Serious or Rare Side Effects: - Seizures: increased risk, monitor patients with epilepsy. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention. - Hepatic dysfunction: elevated liver enzymes, monitor liver function tests. - Suicidal ideation: emergence of depressive thoughts, assess mental health regularly. - Stevens‑Johnson syndrome: rare skin reaction, discontinue if signs appear.

Memantine should be used with caution in patients with the following considerations: - Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: use with caution; monitor liver enzymes. - History of seizures: monitor for increased seizure frequency. - Concurrent use with other NMDA antagonists: avoid combined therapy. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Memantine may interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Ketamine: combined NMDA antagonism may cause excessive CNS depression. - Other NMDA antagonists: avoid concurrent use. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase memantine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): decrease memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce cognitive benefit of memantine. - Diuretics: monitor for potential hypotension or electrolyte imbalance.